8-K: Rani Therapeutics Secures $60.3M, Expands Hemophilia Partnership

Rani Therapeutics Holdings, Inc. announced a $60.3 million private placement, a debt conversion, and a strategic collaboration with Chugai Pharmaceutical for an oral hemophilia product.

Summary

• Rani Therapeutics Holdings, Inc. (RANI) entered into a Securities Purchase Agreement on October 16, 2025, for a private placement raising approximately $60.3 million in gross proceeds.
• The private placement involves the issuance of 42,633,337 shares of Class A Common Stock, warrants to purchase up to 125,000,004 shares (Common Warrants), and pre-funded warrants to purchase up to 82,366,667 shares (Pre-Funded Warrants).
• Institutional Investors purchased shares at $0.48 per share, while an Affiliated Investor (Mir Imran, a Board member) purchased shares at $0.605 per share.
• Pre-Funded Warrants were purchased at $0.4799 per warrant, with an exercise price of $0.0001 per share, and are immediately exercisable with an unlimited term.
• Common Warrants have an exercise price of $0.48 per share, a five-year term, and become exercisable following stockholder approval.
• The Company will seek stockholder approval for the issuance of shares underlying the Common Warrants within 75 days of the Closing Date.
• Rani LLC, a subsidiary, amended its Loan Agreement with Avenue Venture Opportunities Fund, L.P., converting $6.0 million of outstanding loans into 12,500,000 shares (or Pre-Funded Warrants) and receiving warrants for an additional 12,500,000 shares.
• Rani LLC also entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd., effective October 14, 2025, to develop an oral product for hemophilia using Chugai's antibody and RaniPill HC device.
• Under the Chugai agreement, Rani LLC will receive $10.0 million upfront, up to $18.0 million in technology transfer milestones, up to $57.0 million in development milestones, up to $100.0 million in sales-based milestones, and single-digit royalties on net sales.
• The Company agreed to amend its Certificate of Incorporation to reduce Class B Common Stock votes from ten to one, eliminate stockholder written consent, and include additional stockholder protective provisions, along with conforming changes to its Bylaws and LLC Agreement, and terminate the Tax Receivable Agreement.

Sentiment

Score: 8

Explanation: The filing indicates a strong positive outlook due to a significant capital raise, a strategic collaboration with a major pharmaceutical company, and a reduction in debt through conversion. These actions substantially improve the company's financial position and validate its core technology, despite the inherent dilution from the share issuance.

Positives

• Secured approximately $60.3 million in gross proceeds from a private placement, significantly bolstering capital.
• Established a strategic collaboration with Chugai Pharmaceutical Co., Ltd. for an oral hemophilia product, including a $10.0 million upfront payment and potential milestones up to $175.0 million plus royalties.
• Converted $6.0 million of existing debt into equity and warrants with Avenue Venture Opportunities Fund, L.P., reducing financial obligations.
• Gained commitments for board representation from key investors (Samsara BioCapital and Anomaly Ventures, LLC), indicating strong investor confidence and alignment.
• The collaboration with Chugai leverages Rani's RaniPill HC oral delivery device for a high-value therapeutic area (hemophilia), validating its technology.

Negatives

• The private placement will result in significant dilution for existing shareholders due to the issuance of new shares and warrants.
• Placement agent fees of approximately 6.0% of the aggregate purchase price, plus expenses, will reduce the net proceeds from the capital raise.
• The Affiliated Investor (Mir Imran) purchased shares at a higher price ($0.605 per share) compared to Institutional Investors ($0.48 per share), which could be perceived negatively by some investors.
• Stockholder approval is required for the Common Warrants to become exercisable, introducing a potential hurdle and delay for full warrant exercise.

Risks

• Failure to obtain stockholder approval for the issuance of shares underlying the Common Warrants could limit the full capital raise potential and investor rights.
• The development and commercialization of the hemophilia product with Chugai are subject to clinical, regulatory, and market risks inherent in pharmaceutical development.
• The issuance of new shares and warrants will dilute the ownership and voting power of current shareholders.
• The Company faces potential liquidated damages if it fails to timely register the resale of securities or maintain public information requirements under Rule 144.
• The company's ability to maintain its listing on Nasdaq and comply with its rules and regulations is crucial for investor liquidity.

Future Outlook

The Company plans to use the net proceeds from the private placement for working capital. It will seek stockholder approval for the issuance of shares underlying the Common Warrants within 75 days of the closing. The collaboration with Chugai Pharmaceutical aims to advance the development, regulatory approval, and commercialization of an oral hemophilia product, with shared development responsibilities and Chugai leading clinical, regulatory, and commercial activities.

Industry Context

This announcement positions Rani Therapeutics as a key player in the oral drug delivery space, particularly for biologics, through its RaniPill HC device. The collaboration with Chugai Pharmaceutical, a major pharmaceutical company, for a hemophilia antibody product highlights the potential of oral delivery for complex therapies, a significant trend in the pharmaceutical industry aiming to improve patient convenience and adherence. The capital raise provides essential funding for continued development in a highly competitive and capital-intensive biotech sector.

Management Changes

Corporate Governance

Related Party Transactions

• Mir Imran, a member of the Company's Board of Directors, participated in the private placement as an Affiliated Investor, purchasing shares at $0.605 per share.
• Avenue Venture Opportunities Fund, L.P., a lender to Rani LLC, agreed to convert $6.0 million of outstanding loans into 12,500,000 shares (or Pre-Funded Warrants) and received warrants for an additional 12,500,000 shares.

Stakeholder Impact

• Shareholders will experience dilution from the issuance of new shares and warrants, but the capital raise and strategic partnership could enhance long-term value.
• New investors (Institutional Investors, Mir Imran, Samsara BioCapital, Anomaly Ventures, LLC) gain significant equity positions and, in some cases, board representation rights.
• Employees may benefit from increased company stability and potential growth opportunities stemming from the new funding and collaboration.
• Chugai Pharmaceutical Co., Ltd. gains exclusive worldwide rights to develop and commercialize a hemophilia product using Rani's technology, expanding its pipeline.
• Creditors, particularly Avenue Venture Opportunities Fund, L.P., converted a portion of their debt to equity, reducing the Company's debt burden.

Next Steps

• The Company will file a registration statement with the SEC within 15 days of the Closing Date to cover the resale of the newly issued shares and warrant shares.
• The Company will seek stockholder approval for the issuance of shares underlying the Common Warrants within 75 days following the Closing Date.
• Rani LLC and Chugai Pharmaceutical will collaborate on the development, manufacturing, regulatory approvals, and commercialization of the hemophilia product.
• The Company will amend its Certificate of Incorporation, Bylaws, and LLC Agreement, and terminate the Tax Receivable Agreement within 90 days following the Closing Date.

Key Dates

Recommendation

The filing details a highly positive series of events for Rani Therapeutics. The significant capital raise of $60.3 million provides crucial funding for operations and development. More importantly, the strategic collaboration with Chugai Pharmaceutical for an oral hemophilia product, including a substantial upfront payment and potential milestones, validates Rani's core technology and opens a major market opportunity. The debt conversion further strengthens the balance sheet. While dilution is a factor, the overall financial strengthening and strategic validation outweigh this, suggesting strong future growth potential for the company.

Keywords

Private Placement, Warrants, Pre-Funded Warrants, Capital Raise, Biotechnology, Pharmaceutical, Hemophilia, Oral Drug Delivery, RaniPill HC, Chugai Pharmaceutical, SEC Filing, Corporate Governance, Debt Conversion, Strategic Partnership